Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov 12:12:965-973.
doi: 10.2147/JBM.S338556. eCollection 2021.

Outcomes of Patients Who Undergo Transfusion of Fresh Frozen Plasma: A Prospective, Observational, Multicentre Cohort Study in Hiroshima, Japan

Aya Sugiyama  1 , Teruhisa Fujii  2   3 , Yoshiko Okikawa  4 , Fumie Sasaki  5 , Masazumi Okajima  3   6 , Hidekuni Hidaka  3   7 , Koji Iwato  3   8 , Kazuyoshi Sato  3   9 , Akira Kokubunji  3   10 , Noboru Takata  3   11 , Masahiro Yamamoto  3   12 , Junko Tanaka  1   3
Affiliations

Outcomes of Patients Who Undergo Transfusion of Fresh Frozen Plasma: A Prospective, Observational, Multicentre Cohort Study in Hiroshima, Japan

Aya Sugiyama et al. J Blood Med. .

Abstract

Purpose: Given the chronic shortage of blood for transfusion in Japan, promotion of appropriate use of fresh frozen plasma (FFP) urgently needs to be addressed by the national blood project in Japan. Whether FFP transfusions are administered appropriately in Japan is currently unclear. In this study, we aimed to investigate the outcomes of patients who undergo FFP transfusion and the appropriateness of use of FFP.

Patients and methods: This multicentre, prospective, observational cohort study was conducted from September 2017 to April 2019 at the 15 medical institutions in Hiroshima Prefecture that are the top providers of FFP. All patients who underwent FFP transfusion during the study period were included, relevant data being extracted from the medical records. The indications for FFP transfusion were classified in accordance with the Guidelines of the Ministry of Health, Labour and Welfare of Japan. Factors associated with patient outcomes at day 28 after FFP transfusion were subjected to multivariable logistic regression analysis.

Results: In total, data of 1299 patients were eligible for analysis. At least 63.8% of indications for FFP were in accordance with the guideline for FFP transfusions. The mortality rate at day 28 after FFP transfusion was 16.2%. Older age (65-74 years: adjusted odds ratio [AOR]=4.3, ≥75 years: AOR=4.1), non-perioperative use (AOR=4.5), coagulopathy associated with liver damage (AOR=2.7), large volume of FFP transfused (AOR=2.5), and lack of improvement in blood coagulation following FFP transfusion were independently and significantly associated with death within 28 days after FFP transfusion.

Conclusion: Our findings do not support the simple conclusion that FFP transfusions contribute to prognosis. However, given that coagulopathy in patients with end-stage liver disease is infrequently improved by FFP transfusion, "inappropriate" use of FFP should be avoided. It is important to promote appropriate use of FFP so as not to waste blood resources.

Keywords: coagulopathy; compliance with guideline; inappropriate use; prognosis.

PubMed Disclaimer

Conflict of interest statement

Dr Masazumi Okajima reports grants from Ministry of Health, Labour and Welfare of Japan, during the conduct of the study; personal fees from Chugai Pharmaceutical Co., Ltd., Taiho Pharma, Johnson and Johnson K. K., Medicaroid Corporation, Eli Lily Japan K. K., Olympus Corporation, and Covidien Japan Inc., outside the submitted work. The authors declare that they have no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Age distribution of patients who underwent FFP transfusion.
Figure 2
Figure 2
Distribution of indications for FFP transfusion, and underlying disease in which the reason for FFP use was ”inappropriate”.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ministry of Health. Labour and welfare of Japan: annual report on national blood project in 2016. Available from: https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000154567.html. Accessed December 9, 2020.
    1. Ministry of Health. Labour and welfare of Japan: annual report on national blood project in 2020. Available from: https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000063233.html. Accessed August 4, 2021.
    1. Ministry of Health. Labour and welfare of Japan: the guideline for the use of blood products. First edition. Available from: https://www.mhlw.go.jp/new-info/kobetu/iyaku/kenketsugo/5tekisei3b.html. Accessed December 7, 2020.
    1. Ministry of Health. Labour and welfare of Japan: the guideline for the use of blood products (revised in 2017). Available from: https://www.mhlw.go.jp/file/06-Seisakujouhou-11120000-Iyakushokuhinkyoku.... Accessed December 9, 2020.
    1. Liumbruno G, Bennardello F, Lattanzio A, et al. Recommendations for the transfusion of plasma and platelets. Blood Transfus. 2009;7:132–150. - PMC - PubMed